High Dose Epirubicin for Lung Cancer
Author Information
Author(s): E.F. Smit, H.H. Berendsen, D.A. Piers, J. Smeets, A. Riva, P.E. Postmus
Primary Institution: University Hospital Groningen
Hypothesis
Can high-dose epirubicin improve treatment outcomes in patients with unresectable non-small cell lung cancer?
Conclusion
High-dose epirubicin shows moderate activity against advanced non-small cell lung cancer with manageable toxicity.
Supporting Evidence
- Nine partial responses were observed, indicating a 36% response rate.
- Eleven patients experienced disease stabilization, accounting for 44% of the sample.
- Median survival for all patients was 32 weeks, with some patients surviving over 116 weeks.
Takeaway
This study tested a strong medicine called epirubicin on patients with lung cancer that couldn't be removed by surgery. It helped some patients feel better without causing too many bad side effects.
Methodology
Patients received high-dose epirubicin every three weeks, with dose adjustments based on side effects.
Limitations
The study had a small sample size and was limited to patients with specific eligibility criteria.
Participant Demographics
The median age of participants was 58 years, with a majority being male.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI: 18-57.5%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website